BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 24202191)

  • 1. Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.
    Fabritius M; Chtioui H; Battistella G; Annoni JM; Dao K; Favrat B; Fornari E; Lauer E; Maeder P; Giroud C
    Anal Bioanal Chem; 2013 Dec; 405(30):9791-803. PubMed ID: 24202191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.
    Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R
    J Anal Toxicol; 2019 May; 43(4):233-258. PubMed ID: 30615181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.
    Desrosiers NA; Himes SK; Scheidweiler KB; Concheiro-Guisan M; Gorelick DA; Huestis MA
    Clin Chem; 2014 Apr; 60(4):631-43. PubMed ID: 24563491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Δ(9) -tetrahydrocannabinol detection using DrugWipe5S(®) screening and oral fluid quantification after Quantisal™ collection for roadside drug detection via a controlled study with chronic cannabis users.
    Wille SM; Di Fazio V; Toennes SW; van Wel JH; Ramaekers JG; Samyn N
    Drug Test Anal; 2015 Mar; 7(3):178-86. PubMed ID: 24753449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?
    Desrosiers NA; Lee D; Concheiro-Guisan M; Scheidweiler KB; Gorelick DA; Huestis MA
    Clin Chem; 2014 Feb; 60(2):361-72. PubMed ID: 24185550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
    Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
    Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.
    Anizan S; Milman G; Desrosiers N; Barnes AJ; Gorelick DA; Huestis MA
    Anal Bioanal Chem; 2013 Oct; 405(26):8451-61. PubMed ID: 23954944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females.
    Spindle TR; Cone EJ; Herrmann ES; Mitchell JM; Flegel R; LoDico C; Bigelow GE; Vandrey R
    J Anal Toxicol; 2020 Oct; 44(7):661-671. PubMed ID: 32591782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between self-report of cannabis use and toxicological detection of THC/THCCOOH in blood and THC in oral fluid in drivers in a roadside survey.
    Van der Linden T; Silverans P; Verstraete AG
    Drug Test Anal; 2014; 6(1-2):137-42. PubMed ID: 23939912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers.
    Newmeyer MN; Desrosiers NA; Lee D; Mendu DR; Barnes AJ; Gorelick DA; Huestis MA
    Drug Test Anal; 2014 Oct; 6(10):1002-10. PubMed ID: 24652685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free and Glucuronide Urine Cannabinoids after Controlled Smoked, Vaporized and Oral Cannabis Administration in Frequent and Occasional Cannabis Users.
    Huestis MA; Sempio C; Newmeyer MN; Andersson M; Barnes AJ; Abulseoud OA; Blount BC; Schroeder J; Smith ML
    J Anal Toxicol; 2020 Oct; 44(7):651-660. PubMed ID: 32369162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. THCCOOH concentrations in whole blood: are they useful in discriminating occasional from heavy smokers?
    Fabritius M; Favrat B; Chtioui H; Battistella G; Annoni JM; Appenzeller M; Dao K; Fornari E; Lauer E; Mall JF; Maeder P; Mangin P; Staub C; Giroud C
    Drug Test Anal; 2014; 6(1-2):155-63. PubMed ID: 24173827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle.
    Niedbala RS; Kardos KW; Fritch DF; Kunsman KP; Blum KA; Newland GA; Waga J; Kurtz L; Bronsgeest M; Cone EJ
    J Anal Toxicol; 2005 Oct; 29(7):607-15. PubMed ID: 16419389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration.
    Swortwood MJ; Newmeyer MN; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA
    Drug Test Anal; 2017 Jun; 9(6):905-915. PubMed ID: 27647820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.
    Cone EJ; Bigelow GE; Herrmann ES; Mitchell JM; LoDico C; Flegel R; Vandrey R
    J Anal Toxicol; 2015 Sep; 39(7):497-509. PubMed ID: 26139312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.
    Lee D; Vandrey R; Mendu DR; Anizan S; Milman G; Murray JA; Barnes AJ; Huestis MA
    Clin Chem; 2013 Dec; 59(12):1770-9. PubMed ID: 23938457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis.
    Huestis MA; Cone EJ
    J Anal Toxicol; 2004 Sep; 28(6):394-9. PubMed ID: 15516285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive cannabis smoke exposure and oral fluid testing.
    Niedbala S; Kardos K; Salamone S; Fritch D; Bronsgeest M; Cone EJ
    J Anal Toxicol; 2004 Oct; 28(7):546-52. PubMed ID: 15516313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.
    Milman G; Schwope DM; Schwilke EW; Darwin WD; Kelly DL; Goodwin RS; Gorelick DA; Huestis MA
    Clin Chem; 2011 Nov; 57(11):1597-606. PubMed ID: 21875944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of recombinant β-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry.
    Sempio C; Scheidweiler KB; Barnes AJ; Huestis MA
    Drug Test Anal; 2018 Mar; 10(3):518-529. PubMed ID: 28815938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.